Cardiac Biomarkers: Technologies and Global Markets

Report Scope

The principal objectives of this report are to: 

• Identify viable technology drivers through a comprehensive look at various platform technologies for cardiac marker segments of the diagnostic testing market.
• Obtain a complete understanding of the leading cardiac markers and their value in terms of diagnostic testing, screening, prognostic monitoring, pharmacogenomic testing, and theranostics, while also appreciating these elements from their basic principles to their applications.
• Discover feasible market opportunities via identification of high-growth applications in different cardiac marker diagnostic testing areas, with a focus on the biggest and fastest-expanding markets for diseases.
• Focus on global industry development through an in-depth analysis of the major world markets for cardiac marker diagnostic testing, including forecasts for growth.
• Present market figures for the current value of the cardiac marker testing market, projections and growth rates. These are taken from the most recently available from the global diagnostics industry. 

By purchasing this study, the reader will gain: 

• An improved understanding of the current state and future of the most exciting cardiac marker diagnostic testing market segments.
• The latest information on the leading companies engaged in research and development (R&D) and products in the cardiac marker diagnostic reagent pipeline with SWOT analyses.
• A leading perspective of recent diagnostic test developments and revelations as well as knowledge of how they will influence selected clinical markets.
• Knowledge of the cardiac diagnostic testing market as an area of growth, research and investment. 

This analysis covers the following categories of the cardiac diagnostic testing segments: 

• AMI.
• Heart failure.
• Brain natriuretic peptide (BNP).
• Myoglobin.
• Homocysteine (Hcy).
• C-reactive protein (CRP).
• Pulmonary embolism (PE) D-dimer test.
• Low-density lipoproteins (LDL) and high-density lipoproteins (HDL).
• Stroke.
• Creatine kinase-myocardial band (CK-MB) and cardiac enzymes.
• Albumin.
• Cardiac markers used in clinical decisions.
• Cardiac markers in renal failure.
• Troponins in non-ischemic heart disease.
• Cardiac panels.
• POC cardiac markers. 

Analyses include charts and graphs measuring product growth and trends within the marketplace. In addition, a discussion of research on various illnesses provides the reader with a deeper understanding of the possibilities for future treatment and avenues for possible R&D budgets. Company-specific information, including sales figures, product pipeline status and R&D trends, is provided throughout the report. In addition, the study: 

• Assesses cardiac marker diagnostic testing market drivers and bottlenecks from the perspective of the medical and scientific communities.
• Discusses the potential benefits of the cardiac marker diagnostic testing market for various sectors of the medical and scientific community.
• Establishes the current total market size and future growth of the cardiac marker diagnostic testing market and analyzes the current size and growth of individual segments.
• Provides current and forecasted market shares by company.
• Discusses profit and business opportunities by diagnostic testing segment.
• Provides strategic recommendations for near-term business opportunities.
• Assesses current commercial uses of the cardiac marker diagnostic testing market. 

Analyst Credentials

PAUL TAYLOR is an independent market researcher and analyst focused on the medical industry working on projects for over 20 years for a variety of prestigious clients including Agilent & Philips Medical Systems, Biomatrix, Inc (Genzyme Corporation), GE Medical Systems (Multiple Projects), Amersham Pharmacia Biotech Limited, Amersham Pharmacia Biotech Limited and Baxter Heathcare. He previously worked for multinational medical device and pharmaceutical companies including Bristol-Myers Squibb, Johnson & Johnson and Pfizer on developing and implementing strategic business and marketing plans. His predictive analytics knowledge and models of market research data have been used for biopharmaceutical and biotechnology clients. He has a bachelor's degree and Ph.D. degree in biochemistry from the University of Liverpool and an MBA degree for Oxford Brookes University.